0
Articles |

Implications for Macrolide Treatment in Community-Acquired Pneumonia

Linda M. Mundy; David Oldach; Paul G. Auwaerter; Charlotte A. Gaydos; Richard D. Moore; John G. Bartlett; Thomas C. Quinn; Hopkins CAP Team
Author and Funding Information

Affiliations: From the Washington University School of Medicine, St. Louis,  From the University of Maryland School of Medicine, Baltimore,  From the Johns Hopkins School of Medicine, Baltimore,  From the Johns Hopkins School of Medicine, Baltimore; and the National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.

Affiliations: From the Washington University School of Medicine, St. Louis,  From the University of Maryland School of Medicine, Baltimore,  From the Johns Hopkins School of Medicine, Baltimore,  From the Johns Hopkins School of Medicine, Baltimore; and the National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.

Affiliations: From the Washington University School of Medicine, St. Louis,  From the University of Maryland School of Medicine, Baltimore,  From the Johns Hopkins School of Medicine, Baltimore,  From the Johns Hopkins School of Medicine, Baltimore; and the National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.

Affiliations: From the Washington University School of Medicine, St. Louis,  From the University of Maryland School of Medicine, Baltimore,  From the Johns Hopkins School of Medicine, Baltimore,  From the Johns Hopkins School of Medicine, Baltimore; and the National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.

Affiliations: From the Washington University School of Medicine, St. Louis,  From the University of Maryland School of Medicine, Baltimore,  From the Johns Hopkins School of Medicine, Baltimore,  From the Johns Hopkins School of Medicine, Baltimore; and the National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.

Affiliations: From the Washington University School of Medicine, St. Louis,  From the University of Maryland School of Medicine, Baltimore,  From the Johns Hopkins School of Medicine, Baltimore,  From the Johns Hopkins School of Medicine, Baltimore; and the National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.

Affiliations: From the Washington University School of Medicine, St. Louis,  From the University of Maryland School of Medicine, Baltimore,  From the Johns Hopkins School of Medicine, Baltimore,  From the Johns Hopkins School of Medicine, Baltimore; and the National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.

Affiliations: From the Washington University School of Medicine, St. Louis,  From the University of Maryland School of Medicine, Baltimore,  From the Johns Hopkins School of Medicine, Baltimore,  From the Johns Hopkins School of Medicine, Baltimore; and the National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.


Affiliations: From the Washington University School of Medicine, St. Louis,  From the University of Maryland School of Medicine, Baltimore,  From the Johns Hopkins School of Medicine, Baltimore,  From the Johns Hopkins School of Medicine, Baltimore; and the National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.

1998 by the American College of Chest Physicians


Chest. 1998;113(5):1201-1206. doi:10.1378/chest.113.5.1201
Text Size: A A A
Published online

Abstract

Study objectives: To identify associated clinical parameters, concurrent respiratory tract infections, and the association between macrolide-based therapy and mortality in patients with community-acquired pneumonia ascribed to atypical.

Design: Secondary analysis of prospective, cross-sectional study.

Setting: Tertiary care hospital.

Patients: Three hundred eighty-five consecutive patients who were admitted to the Johns Hopkins Hospital from November 11, 1990, through November 10, 1991, and treated for community-acquired pneumonia.

Results: An atypical pathogen was identified in 29 of 385 adults (7.5%). A second pathogen was detected in 16 of 29 patients (55.2%) in whom an atypical pathogen was detected, compared with 13 of 137 patients (9.5%) in whom conventional bacterial pathogens were detected (odds ratio, 10.22; 95% confidence interval, 3.7 to 28.8; p<0.0001), During hospitalization, only four patients (13.8%) with detection of an atypical pathogen received at least 7 days of either a macrolide or tetracycline. No patient identified to have an atypical pathogen died. For patients who either provided paired sera or who died, 24 of 197 (12.2%) had atypical pathogens detected.

Conclusions: Despite vigorous study methods, atypical pathogens were uncommon in our hospitalized population. A second concurrent respiratory pathogen was identified for most patients with atypical pneumonia. Although macrolide use was rare in this patient population, mortality was zero for patients in whom an atypical pathogen was detected, affirming that macrolide-based therapy need not be routine in the therapeutic management of community-acquired pneumonia.


Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Pleuromutilins: Potent Drugs for Resistant Bugs-Mode of Action and Resistance. Cold Spring Harb Perspect Med Published online Oct 14, 2016;
Solithromycin for the treatment of community-acquired bacterial pneumonia. Expert Rev Respir Med Published online Oct 31, 2016;
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543